Enliven Therapeutics Director Lori Anne Kunkel sold 10,000 shares of common stock for approximately $345,000 on June 5, 2026, according to an SEC filing. The sale, executed under a Rule 10b5-1 trading plan adopted in March 2026, reduced her direct holdings by 16% to 51,884 shares. At the time of the transaction, Enliven shares had returned 62.4% over the prior year, and the stock has since surged to a 130% gain over the past 12 months. The clinical-stage biotech is preparing to launch a Phase 3 trial for its chronic myeloid leukemia candidate ELVN-001 later this year and recently strengthened its balance sheet with an upsized public offering that generated roughly $460 million in gross proceeds.
Enliven Therapeutics Inc.Director sold shares under a prearranged plan, but the company has strong stock performance and upcoming Phase 3 trial.